-- Announces Panorama, an OnKure-sponsored, large-scale, multiregional registry designed to characterize the natural disease course and treatment patterns of people living with vascular anomalies -- Executing IND-enablin
Why Is OnKure Therapeutics, Inc. (OKUR) Stock Down Today?
Updated Nov 22, 2026 7:10 AM ET · Prev Close $2.76
Session Regime & Catalyst Assessment
68% Signal ConvictionOnKure Therapeutics, Inc. Pulling Back 2.17% on 0.51x Relative Volume
OnKure Therapeutics, Inc. (OKUR) is pulling back 2.17% (-$0.06) to $2.70 on 0.51x average session volume. Relative to benchmarks, OKUR is outperforming the S&P 500 by +1.47%. 14-day RSI stands at 48.7, keeping momentum in a bearish regime.
-- Announces Panorama, an OnKure-sponsored, large-scale, multiregional registry designed to characterize the natural disease course and treatment patterns of people living with vascular anomalies -- Executing IND-enablin
Price ($2.70) trades relative to 20-day SMA ($2.76) and 50-day SMA ($2.67).
Market & Sector Relative Strength
OKUR outperforming the S&P 500 by +1.47%Recent OKUR Catalyst Headlines
Verified WireBoulder, Colo., Aug. 31, 2026 Globe Newswire -- OnKure Therapeutics, Inc. Nasdaq OKUR , a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that senior mana
-- Executing IND-enabling activities for next-generation PI3Kα pan-mutant selective candidates Oki-345 in breast cancer and Oki-355 in vascular anomalies, with IND submissions planned for 1H 2027 -- Hosted a Key Opinion
OnKure Therapeutics Nasdaq Okur used a scientific webcast to outline its strategy for developing mutant-selective PI3Kα inhibitors, emphasizing allosteric inhibition as a potential way to improve efficacy and tolerabilit
1–3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $2.76 (20-day SMA resistance) for directional breakout confirmation.
Technical Regime (OKUR)
MIXED MA TRENDRetail & Crowd Sentiment
QuietA user on StockTwits expresses bullish sentiment towards $OKUR, praising the Starlight community as the best small-cap community they've found. No recent news articles were available.
About OnKure Therapeutics, Inc.
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and …
Get Instant OKUR Catalyst Alerts
Receive an email alert when OKUR triggers an unusual volume breakout, options sweep, or rating shift.
OKUR Session & Catalyst FAQ
Why is OKUR stock down today?
OnKure Therapeutics, Inc. (OKUR) is pulling back 2.17% (-$0.06) to $2.70 on 0.51x average session volume. Relative to benchmarks, OKUR is outperforming the S&P 500 by +1.47%. 14-day RSI stands at 48.7, keeping momentum in a bearish regime.
Is OKUR stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 0.51x relative volume (low participation). Our multi-factor model currently rates OKUR as AVOID NEW MONEY. Review full valuation, quality, and timing signals on the OKUR Buy or Sell Decision Brief →
What is OKUR's intrinsic value and expected trading range?
At $2.70, OKUR's modeled 1-to-3 session range is $2.57 – $2.83, with a key inflection level at $2.76 (20-day SMA resistance). Compare current price against multi-year cash flow projections in the OKUR Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for OKUR?
RSI at 48.7 reflects soft below-midline momentum. OKUR trades at $2.70 relative to its 20-day SMA ($2.76) and 50-day SMA ($2.67), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.